Meeting
2022 ASCO Annual Meeting
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study.
Authors
Qingyuan Zhang
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
Qingyuan Zhang , Pin Zhang , Min Yan , Xi Yan , Xian Wang , Yuanting Gu , Xiujuan Qu , Shaorong Li , Guoying Xu , Wenhui Yang , Xiaoyu Zhu , Xiaojing Zhang , Binghe Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03481998
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1066)
DOI
10.1200/JCO.2022.40.16_suppl.1066
Abstract #
1066
Poster Bd #
444
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).
First Author: Philippe L. Bedard
First Author: Gabrielle Betty Rocque
Poster
2015 ASCO Annual Meeting
Role of pazopanib (PZ) in modulating hormone resistance in advanced breast cancer (ABC).
First Author: Melanie Catherine Majure
Poster
2012 Breast Cancer Symposium
Safety of everolimus in estrogen receptor–positive advanced breast cancer.
First Author: Alejandra Perez